welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy

Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).

Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.

ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.

First Patient Dosed In Phase II Clinical Trial In Duchenne Muscular Dystrophy